JPH06502550A - αラクトアルブミンを符号化するDNA配列及び使用方法 - Google Patents
αラクトアルブミンを符号化するDNA配列及び使用方法Info
- Publication number
- JPH06502550A JPH06502550A JP5504341A JP50434193A JPH06502550A JP H06502550 A JPH06502550 A JP H06502550A JP 5504341 A JP5504341 A JP 5504341A JP 50434193 A JP50434193 A JP 50434193A JP H06502550 A JPH06502550 A JP H06502550A
- Authority
- JP
- Japan
- Prior art keywords
- lactalbumin
- dna sequence
- sequence
- milk
- bovine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 82
- 108090000942 Lactalbumin Proteins 0.000 title claims abstract description 74
- 102000004407 Lactalbumin Human genes 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims description 38
- 235000021241 α-lactalbumin Nutrition 0.000 title abstract description 42
- 235000013336 milk Nutrition 0.000 claims abstract description 77
- 210000004080 milk Anatomy 0.000 claims abstract description 77
- 239000008267 milk Substances 0.000 claims abstract description 77
- 241000124008 Mammalia Species 0.000 claims abstract description 55
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 22
- 230000001105 regulatory effect Effects 0.000 claims abstract description 22
- 210000000582 semen Anatomy 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 241000283690 Bos taurus Species 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 235000018102 proteins Nutrition 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 37
- 108020004414 DNA Proteins 0.000 claims description 36
- 108010011756 Milk Proteins Proteins 0.000 claims description 35
- 210000000481 breast Anatomy 0.000 claims description 35
- 102000014171 Milk Proteins Human genes 0.000 claims description 34
- 235000021239 milk protein Nutrition 0.000 claims description 32
- 230000002068 genetic effect Effects 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 24
- 108010076119 Caseins Proteins 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 21
- 102000011632 Caseins Human genes 0.000 claims description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 17
- 230000009261 transgenic effect Effects 0.000 claims description 17
- 230000014616 translation Effects 0.000 claims description 15
- 230000028327 secretion Effects 0.000 claims description 13
- 230000035800 maturation Effects 0.000 claims description 10
- 238000012545 processing Methods 0.000 claims description 10
- 235000021247 β-casein Nutrition 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 108020005029 5' Flanking Region Proteins 0.000 claims description 8
- 239000005018 casein Substances 0.000 claims description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 8
- 235000021240 caseins Nutrition 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229930024421 Adenine Natural products 0.000 claims description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- 108091029865 Exogenous DNA Proteins 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 230000001276 controlling effect Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 210000005075 mammary gland Anatomy 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 3
- 108020005065 3' Flanking Region Proteins 0.000 claims description 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 241000282832 Camelidae Species 0.000 claims description 2
- 241000282838 Lama Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 244000309464 bull Species 0.000 claims description 2
- 235000020243 first infant milk formula Nutrition 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 102000020897 Formins Human genes 0.000 claims 2
- 108091022623 Formins Proteins 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 229940039696 lactobacillus Drugs 0.000 claims 2
- HNXRLRRQDUXQEE-ALURDMBKSA-N (2s,3r,4s,5r,6r)-2-[[(2r,3s,4r)-4-hydroxy-2-(hydroxymethyl)-3,4-dihydro-2h-pyran-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC=C[C@H]1O HNXRLRRQDUXQEE-ALURDMBKSA-N 0.000 claims 1
- 241000030939 Bubalus bubalis Species 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 238000012733 comparative method Methods 0.000 claims 1
- 230000001983 lactogenic effect Effects 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 5
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 28
- 108020004707 nucleic acids Proteins 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 239000012634 fragment Substances 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 235000013365 dairy product Nutrition 0.000 description 9
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 3
- 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000014443 Pyrus communis Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 244000309465 heifer Species 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- -1 interlucence Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000009366 Alpha-s1 casein Human genes 0.000 description 1
- 108050000244 Alpha-s1 casein Proteins 0.000 description 1
- 108050001786 Alpha-s2 casein Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102100029464 Aquaporin-9 Human genes 0.000 description 1
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000012045 Casein, beta Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000771413 Homo sapiens Aquaporin-9 Proteins 0.000 description 1
- 101000921370 Homo sapiens Elongation of very long chain fatty acids protein 1 Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229910003177 MnII Inorganic materials 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008195 breast development Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 229940097789 heavy mineral oil Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000025160 regulation of secretion Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (45)
- 1.牛aラクトアルブミンを符号化し哺乳動物の遺伝子イクスプレッションにお いて量的較差をプロモートする乳房特定DNA配列であって、DNA配列は牛a ラクトアルブミンの制御領域における遺伝子構造における異形によって特徴付け られる。
- 2.特許請求の範囲第1項のDNA配列であって該異形の一つが該DNA配列の −13位置である。
- 3.特許請求の範囲第2項のDNA配列であって該−13位置はアデニンによっ て占められている。
- 4.特許請求の範囲第1項のDNA配列であって牛aラクトアルブミンの制御領 域における下記のDNA配列(配列 1D NO:19)よりなる: 【配列があります】
- 5.特許請求の範囲第1項のDNA配列であって牛aラクトアルブミンの制御領 域における下記のDNA配列(配列 ID NO:17)よりなる: 【配列があります】
- 6.特許請求の範囲第1項のDNA配列であって牛aラクトアルブミンの制御領 域における図5に記載されたDNA配列(配列 ID NO:3)よりなる。
- 7.特許請求の範囲第1記載のDNA配列よりなるイクスプレッションベクター 。
- 8.哺乳動物に遺伝的に合体されたときに該哺乳動物の雌種が所望の組み換えタ ンパク質をその乳中に生産することを許容する乳房特定aラクトアルブミン制御 領域構造物よりなるイクスプレッションシステム。
- 9.特許請求の範囲第8項のイクスプレッションシステムであってシグナルペプ チド及びaラクトアルブミンに関するDNA配列暗号づけに操作的にリンクした 少なくとも一つのaラクトアルブミン制御領域構造物よりなる。
- 10.特許請求の範囲第8項のイクスプレッションシステムであってaラクトア ルブミンに関して暗号づけするDNA配列の下流で3′フランキング領域よりな る。
- 11.特許請求の範囲第10項のイクスプレッションシステムであって構造物は シグナルペプチドに関して暗号づけするDNA配列の上流で5′フランキング領 域を含む。
- 12.特許請求の範囲第8項のイクスプレッションシステムであって構造物は牛 βカゼイン遺伝子に付着した5′フランキング領域よりなる。
- 13.特許請求の範囲第12項のイクスプレッションシステムであって構造物は βカゼインのポリアデニレーション部位と5′フランキング量的の略100ベー スペアを含む。
- 14.特許請求の範囲第12項のイクスプレッションシステムであって構造物は 第1の乳タンパク質からの近位プロモータと第2の乳タンパク質の遠位制御領域 とを含む。
- 15.特許請求の範囲第14項のイクスプレッションシスイムであって該第1及 び第2の乳タンパク質はaラクトアルブミン、βカゼイン、aS1カゼイン、a s2カゼイン及びKカゼインからなるグループから選択される。
- 16.特許請求の範囲第12のイクスプレッションシスイムであって構造物はβ カゼインの近位プロモータとaラクトアルブミンの遠位制御領域とを含む。
- 17.乳房組織におけるタンパク質の分泌及び成熟において効果的なシグナルペ プチドに関して暗号づけするDNA配列を用いて乳においてイクスプレスされる べき所望のタンパク質に関して暗号づけする外因性DNA配列に操作的にリンク されたaラクトアルブミン制御領域よりなるイクスプレッションシスイムによっ て特徴付けられた遺伝的処理された哺乳動物。
- 18.特許請求の範囲第17項の遺伝的処理された哺乳動物であって該aラクト アルブミン制御領域は牛aラクトアルブミンを符号化し牛aラクトアルブミンの 制御領域において下記のヌクレオチド配列(配列 ID NO:19)を有する 乳房特定DNA配列を含む: 【配列があります】
- 19.特許請求の範囲第17項の遺伝的処理された哺乳動物であって該aラクト アルブミン制御領域は牛aラクトアルブミンを符号化し牛aラクトアルブミンの 制御領域において下記のヌクレオチド配列(配列 ID NO:20)を有する 乳房特定DNA配列を含む: 【配列があります】
- 20.特許請求の範囲第17項の遺伝的処理された哺乳動物によって生産される 生産物。
- 21.特許請求の範囲第17項の遺伝的処理された哺乳動物によって生産される 精液。
- 22.特許請求の範囲第17項の遺伝的処理された哺乳動物によって生産される 乳。
- 23.特許請求の範囲第17項の遺伝子導入哺乳動物。
- 24.乳房組織におけるaラクトアルブミンの分泌及び成熟を許容するシグナル ペプチドを用いて、乳房特定aラクトアルブミンタンパク質制御領域、または乳 または乳房組織にやいてaラクトアルブミンを特別に活性化するあらゆる制御領 域のイクスプレッションシステムにおいて操作的にリンクされたaラクトアルブ ミンに関し0暗号づけするDNA配列。
- 25.特許請求の範囲第24項のDNA配列であって牛aラクトアルブミンの制 御領域における下記のDNA配列(配列 ID NO:19)よりなる: 【配列があります】
- 26.特許請求の範囲第24項のDNA配列であって牛aラクトアルブミンの制 御領域における下記のDNA配列(配列 1D NO:19)よりなる: 【配列があります】
- 27.特許請求の範囲第24項のDNA配列であって牛aラクトアルブミンの制 御領域における図5に記載されたDNA配列(配列ID NO:3)よりなる。
- 28.乳房組織におけるaラクトアルブミンの分泌及び成熟を許容するシグナル ペプチドに関して暗号づけするDNA配列を用いて所望の組み換えタンパク質を 暗号づけするDNA配列に操作的にリンクされた、aラクトアルブミン制御領域 または乳房組織において特別に活性化されたあらゆる制御領域配列よりなる構造 物の一以上の複製物の合体を遺伝的処理する過程。
- 29.特許請求の範囲第28項の過程であって構造物は遺伝的に哺乳動物に合体 され組み換えタンパク質産物はその後イクスプレスされ乳分泌遺伝的処理哺乳動 物の乳に分泌されまたはそれに加えられる。
- 30.特許請求の範囲第29項の過程であって構造物は哺乳類胚胎、哺乳類乳腺 、または哺乳類幹細胞に遺伝的に合体される。
- 31.特許請求の範囲第28項の過程であって哺乳動物は雌牛、羊、ヤギ、マウ ス、雄牛、ラクダ、水牛、ラマ、及びブタである。
- 32.外因性タンパク質を哺乳動物の乳に生産及び分泌する過程であって、 a.乳房組織内の組み換えタンパク質の分泌及び成熟に効果的なシグナルペプチ ドに関して暗号づけするDNA配列を用いた組み換えタンパク質に関して暗号づ けする外因性DNA配列に操作的にリンクされたaラクトアルブミン制御領域よ りなるイクスプレツシヨンシステムによって特徴づけられた遺伝的処理された哺 乳動物において乳を生産し、 b.該乳を集め、 c.外因性組み換えタンパク質を該乳から分離する過程よりなる。
- 33.特許請求の範囲第32項の過程であって、該イクスプレッションシステム はまたDNA配列の下流でaラクトアルブミンに関して暗号づけする3′フラン キング領域を含む。
- 34.特許請求の範囲第32項の過程であって、該イクスプレッションシステム はまたDNA配列の上流でシグナルペプチド関して暗号づけする5′フランキン グ領域を含む。
- 35.牛aラクトアルブミンを符号化するDNA配列よりなり牛aラクトアルブ ミンの制御領域において図5に記載されたDNA配列(配列 ID NO:3) を有する優秀乳生産哺乳動物を確認するための選択特徴。
- 36.牛aラクトアルブミンを符号化し哺乳動物の遺伝子イクスプレッションに おける量的較差をプロモートする乳房特定DNA配列である遺伝性遺伝的材料よ りなる優秀乳生産哺乳動物を確認するための選択特徴であって、該DNA配列は 牛aラクトアルブミンの制御領域における遺伝子構造における異形によって特徴 付けられる。
- 37.特許請求の範囲第36項の選択特徴であって該異形の一つはDNA配列の −13位置である。
- 38.特許請求の範囲第37項の選択特徴であって該−13位置はアデノシンに よって占められている。
- 39.特許請求の範囲第36項の選択特徴であって牛aラクトアルブミンの制御 傾城における下記のDNA配列(配列 ID NO:19)よるなる: 【配列があります】
- 40.特許請求の範囲第36項の選択特徴であって牛aラクトアルブミンの制御 領域における下記のDNA配列(配列 ID NO:20)よるなる: 【配列があります】
- 41.特許請求の範囲第36項の選択特徴であって牛aラクトアルブミンの制御 領域における図5に記載されたDNA配列(配列ID NO:3)よるなる。
- 42.優秀乳及び乳タンパク質に関して知られた哺乳動物からのaラクトアルブ ミンに関する制御領域のDNA配列上の相似位置を用いて被験哺乳動物において aラクトアルブミンに関する遺伝性制御領域のDNA配列上の選択された位置の 比較よりなる哺乳動物における優秀乳及び乳タンパク質生産予想方法。
- 43.特許請求の範囲第42の方法であって該選択された位置の一つはDNA配 列の制御領域上の−13位置である。
- 44.特許請求の範囲第43の方法であって該−13位置はベースアデニンによ って占められている。
- 45.特許請求の範囲第42の方法であって選択されたDNA配列はステロイド 反応要素よりなる。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74476591A | 1991-08-13 | 1991-08-13 | |
US744,765 | 1991-08-13 | ||
PCT/US1992/006549 WO1993004165A1 (en) | 1991-08-13 | 1992-08-06 | DNA SEQUENCE ENCODING BOVINE α-LACTALBUMIN AND METHODS OF USE |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06502550A true JPH06502550A (ja) | 1994-03-24 |
JP3698369B2 JP3698369B2 (ja) | 2005-09-21 |
Family
ID=24993913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50434193A Expired - Fee Related JP3698369B2 (ja) | 1991-08-13 | 1992-08-06 | αラクトアルブミンを符号化するDNA配列及び使用方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US5530177A (ja) |
EP (1) | EP0555435B1 (ja) |
JP (1) | JP3698369B2 (ja) |
AT (1) | ATE185596T1 (ja) |
AU (1) | AU663101B2 (ja) |
CA (1) | CA2093659C (ja) |
DE (1) | DE69230135T2 (ja) |
DK (1) | DK0555435T3 (ja) |
IL (1) | IL102783A0 (ja) |
NZ (1) | NZ243930A (ja) |
WO (1) | WO1993004165A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4762478B2 (ja) * | 2000-07-03 | 2011-08-31 | キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー | 発現ベクター |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5374523A (en) * | 1992-08-10 | 1994-12-20 | Monsanto Company | Allelic variants of bovine somatotropin gene:genetic marker for superior milk production in bovine |
US5856178A (en) * | 1993-08-30 | 1999-01-05 | Utah State University | DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same |
AU1454495A (en) * | 1993-12-29 | 1995-07-17 | Gene Pharming Europe Bv | Recombinant production of modified proteins lacking certain amino acids |
GB9425326D0 (en) * | 1994-12-15 | 1995-02-15 | Ppl Therapeutics Scotland Ltd | Gene constructs |
US5780009A (en) * | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
US5907080A (en) * | 1995-11-30 | 1999-05-25 | Nexia Biotechnologies, Inc. | Method for development of transgenic dwarf goats |
AU4503497A (en) | 1996-09-26 | 1998-04-17 | Leinwand, Leslie A. | Transgenic model for heart failure |
US5968809A (en) * | 1997-04-11 | 1999-10-19 | Abbot Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
WO1999005574A1 (en) * | 1997-07-25 | 1999-02-04 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
WO1999009816A1 (de) * | 1997-08-22 | 1999-03-04 | Roche Diagnostics Gmbh | Verfahren zur gewinnung von insulin precursorproteinen |
GB9718908D0 (en) | 1997-09-05 | 1997-11-12 | Rowett Research Services Limit | Proteins |
EP1025244A2 (en) * | 1997-10-20 | 2000-08-09 | Genzyme Transgenics Corporation | NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS |
US20030224415A1 (en) * | 2001-06-29 | 2003-12-04 | Gala Design, Inc. | Selection free growth of host cells containing multiple integrating vectors |
KR100868594B1 (ko) * | 2000-07-03 | 2008-11-13 | 갈라 디자인, 인크. | 다수의 통합 벡터를 함유하는 숙주 세포 |
AU2001271614B2 (en) * | 2000-07-03 | 2007-05-31 | Catalent Pharma Solutions, Llc | Host cells containing multiple integrating vectors |
US20040235173A1 (en) * | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
WO2002014473A2 (en) * | 2000-08-15 | 2002-02-21 | Board Of Trustees Of The University Of Illinois | Animals expressing exogenous igf-i in their milk |
DK1463759T3 (da) | 2002-01-07 | 2013-08-12 | Euroscreen Sa | Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf |
US7384738B2 (en) * | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
US20040038304A1 (en) * | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
GB0314856D0 (en) | 2003-06-25 | 2003-07-30 | Unitargeting Res As | Protein expression system |
US20050221429A1 (en) * | 2004-01-16 | 2005-10-06 | Cardinal Health Pts, Llc | Host cells containing multiple integrating vectors comprising an amplifiable marker |
EP1720888A4 (en) | 2004-02-20 | 2009-09-16 | Burnham Inst | ANTIMICROBIAL GLUCOSE AND METHODS OF MAKING |
JP2006168685A (ja) * | 2004-12-20 | 2006-06-29 | Yamaha Marine Co Ltd | 船外機 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7879987A (en) * | 1986-08-28 | 1988-03-24 | Immunex Corp. | Expression of heterologous proteins by transgenic lactating mammals |
ATE140027T1 (de) * | 1989-12-01 | 1996-07-15 | Pharming Bv | Herstellung rekombinanter polypeptide durch rinder und transgene methoden |
-
1992
- 1992-08-06 CA CA002093659A patent/CA2093659C/en not_active Expired - Lifetime
- 1992-08-06 WO PCT/US1992/006549 patent/WO1993004165A1/en active IP Right Grant
- 1992-08-06 DK DK92916978T patent/DK0555435T3/da active
- 1992-08-06 JP JP50434193A patent/JP3698369B2/ja not_active Expired - Fee Related
- 1992-08-06 AT AT92916978T patent/ATE185596T1/de active
- 1992-08-06 EP EP92916978A patent/EP0555435B1/en not_active Expired - Lifetime
- 1992-08-06 AU AU24119/92A patent/AU663101B2/en not_active Expired
- 1992-08-06 DE DE69230135T patent/DE69230135T2/de not_active Expired - Lifetime
- 1992-08-11 IL IL102783A patent/IL102783A0/xx unknown
- 1992-08-12 NZ NZ243930A patent/NZ243930A/en unknown
-
1993
- 1993-06-04 US US08/071,601 patent/US5530177A/en not_active Expired - Lifetime
-
1996
- 1996-03-22 US US08/621,100 patent/US5850000A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4762478B2 (ja) * | 2000-07-03 | 2011-08-31 | キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー | 発現ベクター |
Also Published As
Publication number | Publication date |
---|---|
DK0555435T3 (da) | 2000-04-25 |
EP0555435A4 (ja) | 1995-05-24 |
AU663101B2 (en) | 1995-09-28 |
EP0555435A1 (en) | 1993-08-18 |
DE69230135D1 (de) | 1999-11-18 |
EP0555435B1 (en) | 1999-10-13 |
JP3698369B2 (ja) | 2005-09-21 |
WO1993004165A1 (en) | 1993-03-04 |
DE69230135T2 (de) | 2000-06-21 |
US5850000A (en) | 1998-12-15 |
IL102783A0 (en) | 1993-01-31 |
NZ243930A (en) | 1995-02-24 |
CA2093659A1 (en) | 1993-02-14 |
AU2411992A (en) | 1993-03-16 |
ATE185596T1 (de) | 1999-10-15 |
US5530177A (en) | 1996-06-25 |
CA2093659C (en) | 2001-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06502550A (ja) | αラクトアルブミンを符号化するDNA配列及び使用方法 | |
Brophy et al. | Cloned transgenic cattle produce milk with higher levels of β-casein and κ-casein | |
RU2095414C1 (ru) | Трансген для получения рекомбинантного полипептида в молоке трансгенных коров, способ получения трансгенной коровы (варианты), молоко от трансгенной коровы, пищевой состав | |
US5633076A (en) | Method of producing a transgenic bovine or transgenic bovine embryo | |
EP0807170B1 (en) | Transgenic pigs expressing human coagulation factor viii | |
JP3670003B2 (ja) | ウシ種による組み換えポリペプチドの製造及びトランスジェニック法 | |
Bleck et al. | Correlation of the α-lactalbumin (+ 15) polymorphism to milk production and milk composition of Holsteins | |
Shamay et al. | Production of the mouse whey acidic protein in transgenic pigs during lactation | |
Araki et al. | Effect of a null mutation of the oviduct-specific glycoprotein gene on mouse fertilization | |
EP0599978A1 (en) | Gene encoding a human beta-casein process for obtaining the protein and use thereof in an infant formula | |
Pieper et al. | Transgenic expression of the muscle-specific intermediate filament protein desmin in nonmuscle cells. | |
EP0424480A1 (en) | Genetic marker for superior milk production in dairy cattle | |
US6518482B2 (en) | Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor | |
Han et al. | Enhancing the antibacterial activities of sow milk via site-specific knock-in of a lactoferrin gene in pigs using CRISPR/Cas9 technology | |
Wall et al. | Synthesis and secretion of the mouse whey acidic protein in transgenic sheep | |
Simons et al. | Transgenic livestock | |
Behboodi et al. | Transgenic production from in vivo‐derived embryos: Effect on calf birth weight and sex ratio | |
JPH10507070A (ja) | Ikarosトランスジェニック細胞及び動物 | |
JPH08511688A (ja) | Ec−sodの形質転換生産 | |
Hosseini Moghaddam et al. | Genotyping of Lactoferrin and CXCR1 Genes in Guilan Native Cows and Its Association with Milk Somatic Cell Score | |
Ward et al. | The creation of transgenic sheep for increased wool productivity | |
Davidescu et al. | GENETIC DIVERSITY OF PINZGAU CATTLE BREED: A SYSTEMATIC REVIEW | |
MUYSSON et al. | The alteration of milk content by genetic engineering and recombinant DNA-mediated selection techniques | |
CA2237356A1 (en) | Methods for diagnosis and treatment of bloom's syndrome | |
CN1114357A (zh) | 利用转基因动物生产重组多肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040406 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041008 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20041028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050509 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050704 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090715 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100715 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110715 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110715 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120715 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |